DG
BLUE

Delek Group’s bluebird bio BLUE Stock Holding History

Delek Group’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-5,858
Closed -$7.73M – 211
2018
Q4 		$7.73M Buy
5,858
+2,924
+100% +$4.49M 0.35% 97
2018
Q3 		$5.51M Buy
+2,934
New +$6.06M 0.23% 123

Other funds holding BLUE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Delek Group's BLUE Position: Q1 2019 in Review

Delek Group sold out of bluebird bio (BLUE) in Q1 2019, closing a stake of 5,858 shares — an estimated $7.73M sold.

Delek Group first reported a position in BLUE in Q3 2018 and held it in 2 quarters. The position peaked at $7.73M in Q4 2018. 288 funds tracked by Wall St. Rank hold BLUE as of Q1 2019.

  • Delek Group reported no remaining bluebird bio position as of Q1 2019 after selling out during the quarter.
  • Delek Group sold 5,858 bluebird bio shares in Q1 2019, an estimated $7.73M.
  • Delek Group first reported a position in bluebird bio in Q3 2018 and held it in 2 quarters.
  • Delek Group's bluebird bio position peaked at $7.73M in Q4 2018.
  • 288 funds tracked by Wall St. Rank held bluebird bio as of Q1 2019.

Based on Delek Group's 13F filing for Q1 2019, filed 13 May 2019.